Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc. is positioned for strong financial growth, with an increased peak revenue estimate of $6.8 billion by 2040, reflecting potential market expansion for its pneumococcal conjugate vaccine (PCV) amid anticipated regulatory support and a universal recommendation for adults over 50. The company's clinical advancements, particularly with the VAX-31 product candidate, demonstrate promising efficacy, as evidenced by its successful Phase 3 results and superior performance compared to existing vaccines, which could attract heightened investor interest in upcoming trial readouts. Furthermore, the strategic adjustments to the VAX-31 trial aimed at enhancing the probabilities of positive outcomes reinforce the firm’s outlook, suggesting a potential for continued stock performance appreciation in the coming years.

Bears say

Vaxcyte Inc. faces significant downside risks primarily stemming from potential delays and setbacks in its research and development, regulatory approvals, and commercial uptake, which could hinder the advancement of its vaccine candidates. The recent underwhelming readout from the VAX-24 Phase 2 trial has contributed to investor skepticism, compounded by the overall market's challenging environment for vaccine stocks due to increased regulatory scrutiny. Additionally, even if Vaxcyte's vaccines achieve clinical success, there remains a risk that they may not be endorsed by national vaccine guidelines, severely limiting their commercial viability.

Vaxcyte (PCVX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.